The PROGRESS Trial- Continued Access:

The PROGRESS Trial- Continued Access:

The objective of the PROGRESS continued access study is to provide patients with moderate, calcific aortic stenosis (AS) the opportunity to receive transcatheter aortic valve replacement (TAVR) using the Edwards SAPIEN 3 heart valve. Emerging evidence indicates that moderate AS is not a benign condition, but rather is associated with increased morbidity and mortality. Currently, outside of this clinical trial, treatment options for patients with moderate AS are limited to medical management and ongoing clinical surveillance.

Eligibility Criteria:

• 65 years of age or older
• Moderate aortic stenosis
• Covered by Medicare

Study Link:

https://clinicaltrials.gov/study/NCT04889872

Study Team Contact:

Scott Ardito, Clinical Research Coordinator

Scott.Ardito@yale.edu

203-785-3866